The finding of superior efficacy of MeVac FmIL-12 in a syngeneic murine colorectal adenocarcinoma model motivated us to generate MeVac vectors encoding human IL-12 for future clinical translation. The gene discussed is SPRR2A; the disease is colorectal adenocarcinoma.